Clinical Trials Logo

Filter by:
NCT ID: NCT02378454 Completed - Healthy Clinical Trials

Multiple Breath Nitrogen Washout in Healthy and Cystic Fibrosis Children

Start date: August 2014
Phase: N/A
Study type: Observational

This study compares the lung clearance index (LCI) in cystic fibrosis and healthy children obtained with two different multiple breath nitrogen washout (MBWN2) devices. Each participants will perform the test (LCI) in duplicate on each device.

NCT ID: NCT02378155 Completed - Clinical trials for Pharmacological Cardioversion of Atrial Fibrillation

Cerebral Oxygen Saturation Measurement During Cardioversion Because of Atrial Fibrillation

Start date: February 2015
Phase: N/A
Study type: Interventional

Near infrared spectroscopy (NIRS) is a technique that measures regional cerebral oxygenation in a non-invasive manner. Through the use of near infrared light, the difference between oxygenated and deoxygenated hemoglobin can be measured. By applying the Lambert-Beer law, a numeric result can be calculated. Since atrial fibrillation (AF) has been linked with an increased risk for the development of neurocognitive deficits, a longer period of AF might be associated with a higher risk for neurocognitive deficits. It is hypothesized that there is an increase in the regional cerebral oxygen saturation (rSO2) of patients with paroxysmal or persistent AF after successful cardioversion.

NCT ID: NCT02375971 Completed - Clinical trials for Retinopathy of Prematurity

RAINBOW Study: RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity

RAINBOW
Start date: December 30, 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study was to determine if intravitreal ranibizumab is superior to laser ablation therapy in the treatment of retinopathy of prematurity (ROP).

NCT ID: NCT02375906 Completed - Hepatitis D Clinical Trials

The Hepatitis Delta International Network

HDIN
Start date: November 2013
Phase:
Study type: Observational [Patient Registry]

Hepatitis delta is a major health problem, not only because of the severity of the disease, but also due to the lack of effective antiviral treatment. To improve the current therapeutic options, a better understanding of the pathophysiology is essential. Reliable research in this direction is only possible with large patient study groups. However, given the geographic distribution of hepatitis delta, larger patient cohorts would only be possible through multicenter collaboration.

NCT ID: NCT02373072 Completed - Clinical trials for Idiopathic Parkinson Disease

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease

Start date: March 2015
Phase: Phase 1
Study type: Interventional

This is a study with two sequential cohorts, each with three treatment periods. Single doses of PF-06649751 will be tested in this study, starting at a low dose and escalating to a dose projected to be under the current limits for drug concentration. Each cohort will aim to achieve approximately 9 completers. Primary endpoint is safety and tolerability, secondary endpoint is MDS-UPDRS part III.

NCT ID: NCT02372357 Completed - Clinical trials for Hematological Malignancy

A New Dosing Regimen for Posaconazole Prophylaxis in Children Based on Body Surface Area

Start date: February 2012
Phase: Phase 4
Study type: Interventional

A new prophylactic posaconazole dosing regimen of 120mg/m² tid is evaluated pharmacologically in children 13 years and younger, suffering from a hematologic malignancy.

NCT ID: NCT02371629 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

A Study of the Efficacy and Safety of NVA237 in Patients With Moderate to Severe COPD

Start date: June 24, 2015
Phase: Phase 4
Study type: Interventional

This study is a post-authorization commitment to the European Medicines Agency (EMA). The study serves to determine whether the treatment of patients with stable, symptomatic Chronic Obstructive Pulmonary Disease (COPD) with the investigational drug NVA237 is efficient and safe. The efficacy and safety of the drug was tested for twice daily dosing against once daily dosing.

NCT ID: NCT02370238 Completed - Clinical trials for Metastatic Breast Cancer

A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer

FRIDA
Start date: July 29, 2015
Phase: Phase 2
Study type: Interventional

The Objectives of this study: The primary objective of the study was to evaluate progression-free survival (PFS) (defined as the number of days between the date of randomization and the date of clinical disease progression (PD) according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1, as assessed by Independent Radiology Review, or death for any cause, whichever occured first) in patients with metastatic triple-negative breast cancer (TNBC) treated with the combination of paclitaxel and orally administered reparixin compared to paclitaxel alone. The secondary objectives were: - To determine overall survival (OS). - To evaluate objective response rates (ORR). - To determine median PFS (mPFS). - To assess the safety of the combination of paclitaxel and orally administered reparixin (referred to as combination treatment).

NCT ID: NCT02369874 Completed - Clinical trials for Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN

Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer

EAGLE
Start date: September 9, 2015
Phase: Phase 3
Study type: Interventional

This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination therapy and MEDI4736 monotherapy versus SoC therapy in the target patient population.

NCT ID: NCT02369653 Completed - Lymphoma Clinical Trials

A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase

Start date: October 22, 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the effect of a blood thinning drug called Apixaban versus no administration of a blood thinning drug, in preventing blood clots in children with leukemia or lymphoma. Patients must be receiving chemotherapy, including asparaginase, and have a central line (a catheter inserted for administration of medications and blood sampling)